All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

10

2023 to 2026

Breakthrough

1

Accelerated

0

Priority review

2

Orphan

3

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
202350
202410
202520
202611

10 approvals

Newest first. Hover a badge for what it means.

  • Lytenava (Bevacizumab-Vikg) · Outlook Therapeutics, Inc.Jul 24, 2026
    Original approval · BLA 761320NovelApproval letter

    To treat patients with neovascular (wet) age-related macular degeneration

  • Differin Epiduo Acne Gel (Adapalene and Benzoyl Peroxide) (Adapalene, Benzoyl Peroxide, Adapalene, Benzoyl Peroxide) · Galderma Labs LpMay 22, 2026
    Original approval · NDA 220736Approval letter
  • Vizz (Aceclidine Hydrochloride) · Lenz TherapJul 31, 2025
    Original approval · NDA 218585NovelApproval letter

    To treat presbyopia

  • Tryptyr (Acoltremon) · Alcon Labs INCMay 28, 2025
    Original approval · NDA 217370NovelApproval letter

    To treat the signs and symptoms of dry eye disease

  • Attruby (Acoramidis Hydrochloride) · Bridgebio PharmaNov 22, 2024
    Original approval · NDA 216540NovelOrphanApproval letter

    To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis

  • Wainua (Autoinjector) (Eplontersen Sodium) · Astrazeneca AbDec 21, 2023
    Original approval · NDA 217388NovelOrphanApproval letter

    To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis

  • Cabtreo (Adapalene, Benzoyl Peroxide, Clindamycin Phosphate) · BauschOct 20, 2023
    Original approval · NDA 216632Approval letter
  • Sohonos (Palovarotene) · IpsenAug 16, 2023
    Original approval · NDA 215559NovelPriority reviewOrphanApproval letter

    To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva

  • Izervay (Avacincaptad Pegol Sodium) · AstellasAug 4, 2023
    Original approval · NDA 217225NovelBreakthrough therapyPriority reviewApproval letter

    To treat geographic atrophy secondary to age-related macular degeneration

  • Miebo (Perfluorohexyloctane) · Bausch and Lomb INCMay 18, 2023
    Original approval · NDA 216675NovelApproval letter

    To treat signs and symptoms of dry eye disease

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.